Shots:
- Autobahn acquires global IP, development, and regulatory rights to ASP3652 to strengthen its brain-targeting chemistry platform. The addition of ASP3652 will accelerate the delivery of next-generation brain-targeting prodrugs for CNS disorders, particularly MS
- ASP3652 complements Autobahn’s brain-targeting chemistry platform, which uses FAAH-mediated prodrug conversion to enable the delivery of small molecules across the BBB. The company may develop ASP3652 in combination with multiple pipeline programs, including Autobahn’s TRβ agonists for MS
- ASP3652 is a FAAH inhibitor, previously been evaluated across 10 clinical studies in ~200 patients
Click here to read full press release/ article | Ref: BUSINESS WIRE | Image: BioSpace
The post Autobahn Acquires Global Rights to Astellas’ ASP3652 to Bolster its Brain Targeting Chemistry Platform first appeared on PharmaShots.
